Somatic hypermutation signature in B-cell low-grade lymphomas

Haematologica

Volumn 93, Issue 8, 2008, Pages 1186-1194

  Tracey, Lorraine ^a   Aggarwal, Mohit ^a   García Cosio, Mónica ^b   Villuendas, Raquel ^a   Algara, Patrocinio ^c   Sánchez Beato, Margarita ^a   Sánchez Aguilera, Abel ^a   García, Juan F ^d   Rodríguez, Antonia ^e   Camacho, Francisca I ^f   Martínez, Nerea ^a   Ruiz Ballesteros, Elena ^c   Mollejo, Manuela ^c   Piris, Miguel Á ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL VIRGEN DE LA SALUD   (Spain)

^d MD ANDERSON CANCER CENTER   (Spain)

^e HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^f HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Lymphomas; Profiling; Somatic hypermutation

Indexed keywords

CYCLIN DEPENDENT KINASE 7; TRANSCRIPTION FACTOR DP1;

AIM2 GENE; ARTICLE; B CELL LYMPHOMA; BUB3 GENE; CCNA2 GENE; CDK2 GENE; CDK7 GENE; CHC1 GENE; CHEK1 GENE; CHROMOSOME; CONTROLLED STUDY; DISEASE MARKER; DNA REPAIR; DNA REPLICATION; E2F5 GENE; FRAP1 GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOME; HMG2 GENE; HOXB7 GENE; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN GENE; JUNB GEN; MCM3 GENE; MED6 GENE; PCNA GENE; POLA GENE; POLS GENE; PRIM1 GENE; PRKDC GENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAD51C GENE; RAD54B GENE; RFC3 GENE; RFC4 GENE; SOMATIC HYPERMUTATION; TCEA2 GENE; TFDP1 GENE; TISSUE MICROARRAY; WEE1 GENE;

B-LYMPHOCYTES; CYTOSINE DEAMINASE; DNA REPAIR; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHOMA, B-CELL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA, NEOPLASM; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN; SPLEEN;

EID: 48749132986     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12999     Document Type: Article

References (36)

1. Frieder D, Larijani M, Tang E, Parsa JY, Basit W, Martin A. Antibody diversification: mutational mechanisms and oncogenesis. Immunol Res 2006;35:75-88.
2. Rajewsky K, Forster I, Cumano A. Evolutionary and somatic selection of the antibody repertoire in the mouse. Science 1987;238:1088-94.
3. Wang L, Jackson WC, Steinbach PA, Tsien RY. Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci USA 2004;101:16745-9.
4. Rada C, Milstein C. The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. Embo J 2001;20:4570-6.
5. Muller-Hermelink HK, Greiner A. Molecular analysis of human immunoglobulin heavy chain variable genes (IgVH) in normal and malignant B cells. Am J Pathol 1998;153:1341-6.
6. Rogozin IB, Kolchanov NA. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. Biochim Biophys Acta 1992;1171:11-8.
7. Kinoshita K, Honjo T. Linking class-switch recombination with somatic hypermutation. Nat Rev Mol Cell Biol 2001;2:493-503.
8. Heintel D, Kroemer E, Kienle D, Schwarzinger I, Gleiss A, Schwarzmeier J, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia 2004;18:756-62.
9. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
10. Algara P, Mateo MS, Sanchez-Beato M, Mollejo M, Navas IC, Romero L, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-304.
11. Bertoni F, Conconi A, Cogliatti SB, Schmitz SF, Ghielmini M, Cerny T, et al. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. Br J Haematol 2004;124:289-98.
12. Cogliatti SB, Bertoni F, Zimmermann DR, Henz S, Diss TC, Ghielmini M, et al. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol 2005;206:320-7.
13. Camacho FI, Algara P, Rodriguez A, Ruiz-Ballesteros E, Mollejo M, Martinez N, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood 2003;101:4042-6.
14. Lai R, Lefresne SV, Franko B, Hui D, Mirza I, Mansoor A, et al. Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. Mod Pathol 2006;19:1498-505.
15. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003;101:4944-51.
16. Carreras J, Villamor N, Colomo L, Moreno C, Ramón y Cajal S, Crespo M, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005;205:507-13.
17. Kuppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. Embo J 1993;12:4955-67.
18. Tracey L, Villuendas R, Ortiz P, Dopazo A, Spiteri I, Lombardia L, et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002;161:1825-37.
19. Tracey L, Villuendas R, Dotor AM, Spiteri I, Ortiz P, Garcia JF, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003;102:1042-50.
20. Tracey L, Spiteri I, Ortiz P, Lawler M, Piris MA, Villuendas R. Transcriptional response of T cells to IFN-α: changes induced in IFN-α sensitive and resistant cutaneous T cell lymphoma. J Interf Cyt Res 2004;24:185-95.
21. Martinez-Delgado B, Melendez B, Cuadros M, Alvarez J, Castrillo JM, Ruiz De La Parte A, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 2004;10:4971-82.
22. Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, et al. Expression of the NF-κB targets BCL2 and BIRC5/survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005;206:123-34.
23. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, Camacho FI, Algara P, Martinez N, et al. Splenic marginal zone lymphoma. Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005; 106:1831-8.
24. Martinez N, Camacho FI, Algara P, Rodriguez A, Dopazo A, Ruiz-Ballesteros E, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63:8226-32.
25. Miller RG. Beyond Anova. New York, Chapman & Hall. 1997.
26. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: a novel functional genomics compendium with automated data mining and query reformulation support. Bioinformatics 1998;14:656-64.
27. Rebhan M, Chalifa-Caspi V, Prilusky J, Lancet D. GeneCards: integrating information about genes, proteins and diseases. Trends Genet 1997;13:163.
28. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, Stam RW, et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006;10:331-42.
29. Shaffer AL, Rosenwald A, Hurt EM, Giltnane JM, Lam LT, Pickeral OK, et al. Signatures of the immune response. Immunity 2001;15:375-85.
30. Rodríguez A, Martínez N, Camacho FI, Ruíz- Ballesteros E, Algara P, García JF, et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 2004;10:6796-806.
31. Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A, et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005;23:3780-92.
32. Rodriguez A, Villuendas R, Yanez L, Gomez ME, Diaz R, Pollan M, et al. Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. Leukemia 2007;21:1984-91.
33. Kienle D, Benner A, Krober A, Winkler D, Mertens D, Buhler A, et al. Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. Blood 2006;107:2090-3.
34. Winter DB, Gearhart PJ. Altered spectra of hypermutation in DNA repair-deficient mice. Philos Trans R Soc Lond B Biol Sci 2001;356:5-11.
35. Bemark M, Sale JE, Kim HJ, Berek C, Cosgrove RA, Neuberger MS. Somatic hypermutation in the absence of DNA-dependent protein kinase catalytic subunit (DNA-PK(cs)) or recombination-activating gene (RAG)1 activity. J Exp Med 2000;192:1509-14.
36. Pasqualucci L, Guglielmino R, Houldsworth J, Mohr J, Aoufouchi S, Polakiewicz R, et al. Expression of the AID protein in normal and neoplastic B cells. Blood 2004;104:3318-25.